Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Identifieur interne : 004D74 ( Ncbi/Merge ); précédent : 004D73; suivant : 004D75Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Auteurs : R. Pahwa [États-Unis] ; K. Lyons ; D. Mcguire ; P. Silverstein ; F. Zwiebel ; M. Robischon ; W C KollerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Analysis of Variance, Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Area Under Curve, Carbidopa (pharmacokinetics), Carbidopa (therapeutic use), Delayed-Action Preparations, Drug Therapy, Combination, Female, Humans, Intervention Studies, Levodopa (pharmacokinetics), Levodopa (therapeutic use), Longitudinal Studies, Male, Matched-Pair Analysis, Motor Skills (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Quality of Life, Sickness Impact Profile.
- MESH :
- chemical , pharmacokinetics : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug effects : Motor Skills.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- Activities of Daily Living, Aged, Analysis of Variance, Area Under Curve, Delayed-Action Preparations, Drug Therapy, Combination, Female, Humans, Intervention Studies, Longitudinal Studies, Male, Matched-Pair Analysis, Quality of Life, Sickness Impact Profile.
Abstract
We compared clinical, pharmacokinetic, and quality-of-life measures in patients with Parkinson's disease (PD) who were on standard carbidopa-levodopa (Std-L) and after conversion to sustained-release carbidopa-levodopa 50/200 (L-CR). A total of 20 PD patients with motor fluctuations participated in the study and 18 completed it. There were 10 women and eight men, with a mean age of 67.5 years and a mean disease duration of 9.9 years. All patients underwent 10-h pharmacokinetic and clinical evaluations while on Std-L and again while on L-CR. The patients maintained diaries for 2 days before the 10-h evaluations and completed a sickness impact profile (SIP) while on Std-L and again while on L-CR. The total daily levodopa intake was significantly greater with L-CR because of the reduced bioavailability of the L-CR. The mean daily levodopa dosage was 569 mg for Std-L compared with 751 mg for L-CR. The patients performed better in walking time, Unified Parkinson's Disease Rating Scale (motor score), and tapping total with L-CR, although the improvement was not statistically significant. There was no significant difference in dyskinesias between the two preparations. The plasma levodopa levels and the areas under the curve were significantly greater with L-CR. "On" time as measured by patient diaries was significantly greater for L-CR. There was no significant difference in the total SIP scores for patients on the two preparations, but patients had significantly better home management and mobility while on L-CR. In conclusion, L-CR resulted in more "on" time with greater plasma levodopa levels, which resulted in better home management and mobility.
DOI: 10.1002/mds.870120508
PubMed: 9380047
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004609
- to stream PubMed, to step Curation: 004609
- to stream PubMed, to step Checkpoint: 004689
Links to Exploration step
pubmed:9380047Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R" last="Pahwa">R. Pahwa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City 66160</wicri:regionArea><wicri:noRegion>Kansas City 66160</wicri:noRegion></affiliation></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K" last="Lyons">K. Lyons</name></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D" last="Mcguire">D. Mcguire</name></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P" last="Silverstein">P. Silverstein</name></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F" last="Zwiebel">F. Zwiebel</name></author><author><name sortKey="Robischon, M" sort="Robischon, M" uniqKey="Robischon M" first="M" last="Robischon">M. Robischon</name></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W C" last="Koller">W C Koller</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9380047</idno><idno type="pmid">9380047</idno><idno type="doi">10.1002/mds.870120508</idno><idno type="wicri:Area/PubMed/Corpus">004609</idno><idno type="wicri:Area/PubMed/Curation">004609</idno><idno type="wicri:Area/PubMed/Checkpoint">004689</idno><idno type="wicri:Area/Ncbi/Merge">004D74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R" last="Pahwa">R. Pahwa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City 66160</wicri:regionArea><wicri:noRegion>Kansas City 66160</wicri:noRegion></affiliation></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K" last="Lyons">K. Lyons</name></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D" last="Mcguire">D. Mcguire</name></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P" last="Silverstein">P. Silverstein</name></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F" last="Zwiebel">F. Zwiebel</name></author><author><name sortKey="Robischon, M" sort="Robischon, M" uniqKey="Robischon M" first="M" last="Robischon">M. Robischon</name></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W C" last="Koller">W C Koller</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Analysis of Variance</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Area Under Curve</term><term>Carbidopa (pharmacokinetics)</term><term>Carbidopa (therapeutic use)</term><term>Delayed-Action Preparations</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Intervention Studies</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Matched-Pair Analysis</term><term>Motor Skills (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Quality of Life</term><term>Sickness Impact Profile</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Analysis of Variance</term><term>Area Under Curve</term><term>Delayed-Action Preparations</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Intervention Studies</term><term>Longitudinal Studies</term><term>Male</term><term>Matched-Pair Analysis</term><term>Quality of Life</term><term>Sickness Impact Profile</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared clinical, pharmacokinetic, and quality-of-life measures in patients with Parkinson's disease (PD) who were on standard carbidopa-levodopa (Std-L) and after conversion to sustained-release carbidopa-levodopa 50/200 (L-CR). A total of 20 PD patients with motor fluctuations participated in the study and 18 completed it. There were 10 women and eight men, with a mean age of 67.5 years and a mean disease duration of 9.9 years. All patients underwent 10-h pharmacokinetic and clinical evaluations while on Std-L and again while on L-CR. The patients maintained diaries for 2 days before the 10-h evaluations and completed a sickness impact profile (SIP) while on Std-L and again while on L-CR. The total daily levodopa intake was significantly greater with L-CR because of the reduced bioavailability of the L-CR. The mean daily levodopa dosage was 569 mg for Std-L compared with 751 mg for L-CR. The patients performed better in walking time, Unified Parkinson's Disease Rating Scale (motor score), and tapping total with L-CR, although the improvement was not statistically significant. There was no significant difference in dyskinesias between the two preparations. The plasma levodopa levels and the areas under the curve were significantly greater with L-CR. "On" time as measured by patient diaries was significantly greater for L-CR. There was no significant difference in the total SIP scores for patients on the two preparations, but patients had significantly better home management and mobility while on L-CR. In conclusion, L-CR resulted in more "on" time with greater plasma levodopa levels, which resulted in better home management and mobility.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9380047</PMID><DateCreated><Year>1997</Year><Month>11</Month><Day>07</Day></DateCreated><DateCompleted><Year>1997</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>1997</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.</ArticleTitle><Pagination><MedlinePgn>677-81</MedlinePgn></Pagination><Abstract><AbstractText>We compared clinical, pharmacokinetic, and quality-of-life measures in patients with Parkinson's disease (PD) who were on standard carbidopa-levodopa (Std-L) and after conversion to sustained-release carbidopa-levodopa 50/200 (L-CR). A total of 20 PD patients with motor fluctuations participated in the study and 18 completed it. There were 10 women and eight men, with a mean age of 67.5 years and a mean disease duration of 9.9 years. All patients underwent 10-h pharmacokinetic and clinical evaluations while on Std-L and again while on L-CR. The patients maintained diaries for 2 days before the 10-h evaluations and completed a sickness impact profile (SIP) while on Std-L and again while on L-CR. The total daily levodopa intake was significantly greater with L-CR because of the reduced bioavailability of the L-CR. The mean daily levodopa dosage was 569 mg for Std-L compared with 751 mg for L-CR. The patients performed better in walking time, Unified Parkinson's Disease Rating Scale (motor score), and tapping total with L-CR, although the improvement was not statistically significant. There was no significant difference in dyskinesias between the two preparations. The plasma levodopa levels and the areas under the curve were significantly greater with L-CR. "On" time as measured by patient diaries was significantly greater for L-CR. There was no significant difference in the total SIP scores for patients on the two preparations, but patients had significantly better home management and mobility while on L-CR. In conclusion, L-CR resulted in more "on" time with greater plasma levodopa levels, which resulted in better home management and mobility.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zwiebel</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Robischon</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>W C</ForeName><Initials>WC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019540">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003692">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016033">Intervention Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016555">Matched-Pair Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018434">Sickness Impact Profile</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9380047</ArticleId><ArticleId IdType="doi">10.1002/mds.870120508</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W C" last="Koller">W C Koller</name><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K" last="Lyons">K. Lyons</name><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D" last="Mcguire">D. Mcguire</name><name sortKey="Robischon, M" sort="Robischon, M" uniqKey="Robischon M" first="M" last="Robischon">M. Robischon</name><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P" last="Silverstein">P. Silverstein</name><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F" last="Zwiebel">F. Zwiebel</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R" last="Pahwa">R. Pahwa</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004D74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:9380047
|texte= Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:9380047" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |